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Next generation DNA sequencing (NGS) technologies
are increasing in their appeal for studying cancer geno-
mics. High-throughput data and a growing repertoire of
applications that quantitatively measure gene expression,
splicing, noncoding RNAs, and genomic variation are
revealing that cancer is a more complex and heteroge-
neous disease than previously imagined. Fully character-
izing the ~10,000 types and subtypes of cancer that
exist to develop biomarkers that can be used to clini-
cally define tumors and target specific treatments
requires large studies that examine specific tumors in
thousands of patients. This goal will fail without signifi-
cantly reducing both data production and analysis costs,
so that most cancer biologists and clinicians can con-
duct NGS assays and analyze their data in routine ways.
Currently, most cancer biology NGS papers are pub-
lished either by genome centers or through collabora-
tions with instrument vendors. However, this is going to
change rapidly with efforts like the Cancer Genome
Anatomy project. In any case, large teams of bioinfor-
maticians are involved in analyzing data through labor-
intensive processes. With refinements offered by the
Illumina HiSeq 2000, or Life Technologies SOLiD 4, the
cost of collecting data for transcriptome analysis and
mate-pair genome sequencing is sufficiently inexpensive
for small groups and individuals, beyond genome cen-
ters, to conduct the required studies. However, current
data analysis methods need to be automated with estab-
lished tools in scalable and adaptable systems that pro-
vide standard reports to make results available to enable
interactive exploration by biologists and clinicians.
In our presentation, we will examine the time and
costs required to analyze data that will be collected in
future cancer studies. Using data from existing matched
tumor and normal transcriptome studies from random
oral cancer samples, and samples grouped by drinking
and smoking behavior (as a tool to define data analysis
requirements), we will compare the costs of conducting
large studies using current data analysis approaches with
those using integrated software systems to demonstrate
how automation reduces costs, while providing compar-
able results for identifying transcript isoforms, mutations
and novel translocations. Geospiza’s GeneSifter distribu-
ted cloud- based software architecture, including open
source tools, like BioHDF, will be described to share
insights into high performance computing requirements
for scalable data processing.
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